Altre lingue HUTCHMED (China) Limited

Azioni

HCM

KYG4672N1198

Mercato chiuso - London S.E. Altri mercati azionari 17:35:09 26/04/2024			Variaz. 5gg	Var. 1 gen.
290 ^GBX	-4,61%		+7,01%	+2,47%

17:10	Hutchmed prende atto del parere positivo del CHMP per l'approvazione di fruiquintinib	AN
16:07	Il Comitato dell'Agenzia Europea dei Medicinali sostiene l'approvazione di fruquintinib di Takeda per il trattamento del tumore del colon-retto	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	17:40
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	17:10
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	16:07
Hutchmed to Present New Data at US Cancer Research Conference	05/04
HUTCHMED Limited Highlights Data to be Presented at AACR Congress 2024	05/04
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status	03/04
Hutchmed endometrial cancer treatment application accepted for review	02/04
Hutchmed, Innovent Biologics Say Chinese Regulator Accepts Application for Endometrial Cancer Drug Combination	02/04
HSBC in special payout on Canada sale; Astra FDA win	02/04
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status	02/04
Sector Update: Health Care Stocks Advance Premarket Thursday	28/03
Hutchmed lung cancer treatment accepted for review in China	28/03
Hutchmed Says Supplemental New Drug Application for Savolitinib Accepted for Review in China	28/03
JD Sports backs outlook; Spirent accepts new offer	28/03
Hutchmed (China)'s NDA Application Accepted by Chinese Authorities	28/03
HUTCHMED Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC	28/03
Hutchmed begins registration stage for sovleplenib phase 2/3 trial	22/03
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug	22/03
Hutchmed (China) Initiates Phase II/III Clinical Trials for Autoimmune Disease Drug	22/03
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China	22/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue HUTCHMED (China) Limited

Azioni

HCM

KYG4672N1198

Altre lingue

Filtri